Group items tagged

A new research has suggested that meat contributes to the growing global obesity prevalence as much as sugar and moreover it is protein, not the fat present in meat which is a major obesity contributor. Proteins digest slow as compared to fats Carbohydrates and fats not only provide us with enough energy, the body demands, they are also digested faster than protein.

Obesity and Diabetes: A new study has found that twins having higher body mass index (BMI) have increased risk of developing type 2 diabetes.

The Disease They Call FAT is the best treatment for lipedema & obesity & fat metabolism disorder in New York and surrounding the area. The Disease They Call FAT is the opening salvo making clear that there is no turning back in the fight against lipedema.

September is National Childhood Obesity Awareness Month support the cause with custom made silicone wristbands.

Read how to measure weight and take healthy steps for reducing fats. Obesity is excess of your calories stored in adipose tissues as fats. BMI is used for calculating body mass in relation to stronger muscles.

Know healthy food, diet and health tips for obesity in children. Also to know ayurvedic medicine for weight loss. Visit link to know more.

Managing Obesity to Improve Health: New Drugs, Old Drugs is organized by AchieveCE and will be held on Jan 24, 2023

A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.

Eli Lilly's weight-loss medicine Mounjaro, also known as tirzepatide, will be available in the UK within weeks as a four-dose pre-filled injection pen. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug to treat adults with type 2 diabetes and for weight management in obese patients. Branded as Mounjaro KwikPen, the injection is to be used together with a reduced-calorie diet and increased physical activity, the regulator said. "The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people's health, is clear. "This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month's treatment, of one dose per week," said Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access.

Obesity is considered one of the leading causes of illness and premature deaths. Excessive body weight increases the risk of serious life-threatening health conditions such as heart diseases, type 2 diabetes, sleep apnea and certain cancers. Losing weight and maintaining it at a healthy level is the best way to reduce the risk of all these health conditions. But losing weight can be hard for those suffering from severe obesity. This is where the role of bariatric surgery comes into play. Bariatric surgery is considered the most effective weight loss surgery that functions by causing gastric restriction or malapsorption of nutrients or a combination of both these techniques.

Japanese researchers at Okayama University have found that paternal high-fat diet (HFD) intake may lead to a number of changes in next generations including generational obesity and metabolic dysfunction. But, if the next two generations are given controlled diet, the metabolic effects of grand paternal high-fat diet may be diminished.

Low-income moms who move from very poor neighborhoods to less disadvantaged ones lower their risk of becoming extremely obese and developing type 2 diabetes, a new study reveals.

Heavy duty wheelchairs are also often known as "bariatric" wheelchairs. Any home medical products that have high weight capacities, whether they be wheelchairs, commodes, beds or anything else are more commonly referred to as bariatric products in the recent years. Standard or "off the shelf" heavy duty wheelchairs are wheelchairs which will have a weight capacity of somewhere over 350 lbs. Of course, should the need arise custom wheelchairs can be ordered in cases where even heavier weight capacities are required. Features Aluminum footplates are attractive, crack-proof and lightweight Carbon steel frame with TRIPLE coated chrome for an attractive, chip-proof, maintainable finish Comes standard with carry pocket on back rest Composite Mag-style wheels with chrome hand rim are lightweight and maintenance free Padded armrests provide added patient comfort Precision sealed wheel bearings in front and rear ensure long lasting performance and reliability Heavy duty bariatric wheelchairs for the larger user and the obese. Including extra large self propelled wheelchairs, heavy duty transfer wheelchairs and bariatric transport wheelchairs for the larger or obese user.Heavy duty wheelchairs are made with stronger axles, heavier tubing, double cross braces, gusseted frames and reinforced upholstery to be able to handle the weights required. karma km-8520 Item Code:WCI-29 MRP: R 32085 Our Price:R24063 Net Price:R23582( Apply Coupon Code 'MSW2365' Get 2% Discount ) Availability:Not Available Pin Code:Delivery All Over India (Free Shipping) Warranty:1 Year Seat Widths and Depths Seat widths for heavy duty wheelchairs will range from about 20" to about 30" depending on the model chosen. Seat depths for heavy duty wheelchairs will range from about 18" to about 24" depending on the model chosen. Seat Height Seat heights on a heavy duty wheelchair range between 15" and 22" depe

PRODUCT DESCRIPTION META SLIM SLIMMING AND WEIGHT LOSS PRODUCT IN PAKISTAN:OPENTELESHOP MetaSlim is a proven weight loss treatment which uses the most essential of naturals extract to combat this deadly problem. By using MetaSlim regularly the excess of fat/weight can be reduced and the body can gain the desired shape. This also helps in keeping in controlling on ailments such as High Blood Pressure and diabetes.Metaslim is purely a herbal fat loss & slimming formula. The Metaslim Slimming Powder when consumed with the lukewarm water melts & wash away the accimlated fat from the body & whereas the Metaslim Slimming Oil. MetaSlim works competently with your body's physiology. MOST EFFECTIVE ON:OPENTELESHOP 1. Obesity. 2. Indigestion. 3. Gastric problems. 4. Constipation. 5. Stomach Ache. 6. High Blood Pressure etc. There are no special prerequisites for taking this medicine, for maximum results however, take simple and easily digestible food. Avoid fried foods and try to exercise regularly HOW DOES METASLIM WORK? METASLIM WORK IN THREE WAYS:OPENTELESHOP 1. Regular use of MetaSlim breaks down and melts the fat accumulated in your body rapidly. 2. MetaSlim will suppress the untimely and extra appetite and will regulate the digestive system, turning food into energy and not into fat. 3. With the special components used in it, the body looses the tendency to make fat and will result in controlling obesity problem. Tags & Keywords Meta Slim:Openteleshop Weight loss oil,Weight loss oil price,Weight loss oil online,Weight loss oil in pakistan,Weight loss meta slim oil,Metaslim India Oil in Pakistan, Metaslim in pakistan, Metaslim Price, Metaslim Reviews, Metaslim Weight Loss Oil, Metaslim Powder And Oil, Metaslim ingredients, Online Buy Indian Metaslim,Metaslim Price In Lahore,Metaslim Price In Karachi,Metaslim Price In Islamabad,Metaslim Price In quetta,Metaslim Price In Gujrat,Metaslim Price In Jhelum,Metaslim Price In gujranwala,Metaslim Price In peshawar,Metasl

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

Pediatric Obesity 101: Helping to Turn the Tide is organized by Dietitian Central.

Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs. A weekly injection of Wegovy, which was launched in the U.S. in June 2021, leads to an average weight loss of around 15%, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities. But supply issues for Wegovy manufacturer Novo Nordisk means the Danish drugmaker has struggled to meet surging U.S. demand, delaying a launch in most of Europe. Insurers and some national governments have also baulked at its cost, while a minority of patients do not respond to it. Vivus and Currax Pharmaceuticals, U.S.-based developers whose treatments have been on the U.S. market for around a decade, hope to benefit from the attention and supply shortage. But scientists and investors say that lower efficacy plus side effects could continue to hold the treatments back.

Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear. The government's announcement on the £40 million pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the NHS specialist weight management scheme. The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there. British Prime Minister Rishi Sunak said on Wednesday (May 7) the pilot and fighting obesity-related diseases could reduce pressure on hospitals. It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists". The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.

Denmark's Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up a potential contestant in the booming obesity drug market. In a statement on Wednesday (May 10), the partners said that the Phase II dose-finding trial met its primary endpoint of weight loss after 46 weeks. Paola Casarosa, head of therapeutic areas at Germany's Boehringer Ingelheim told Reuters the partners are in discussion with regulators about the design of a planned follow-up trial in the third and last phase of testing. The enormous demand for weight-loss treatments such as Novo Nordisk's Wegovy, or potentially Eli Lilly's Mounjaro, could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. Lilly said about a year ago that Mounjaro was shown to reduce up to 22.5% in weight after 72 weeks of treatment in a much larger late-stage trial.